Show simple item record

dc.contributor.advisorGökcan, Mustafa Kürşat
dc.contributor.authorTaş, Vedat
dc.date.accessioned2020-12-03T12:01:00Z
dc.date.available2020-12-03T12:01:00Z
dc.date.submitted2016
dc.date.issued2020-12-01
dc.identifier.urihttps://acikbilim.yok.gov.tr/handle/20.500.12812/42028
dc.description.abstractAmaç: Bu çalışmada amacımız, sisplatin ototoksisitesinde intratimpanik IGF-1 ve intratimpanik deksametazonun terapötik etkilerinin elektrofizyolojik olarak karşılaştırılmasıdır.Materyal ve Metod: 12 adet sıçana 16 mg/kg tez doz yavaş infüzyon ile intraperitoneal yolla sisplatin enjeksiyonu yapıldı. Sisplatin verilmeden, sisplatin verildikten 72 saat sonra ve İT enjeksiyonlardan sonra BAER yapılarak ABR dalgalarının latans süreleri dökümente edildi. Deney hayvanlarının sağ kulakları kontrol grubu olarak kabul edildi ve intratimpanik salin enjeksiyonu yapıldı. Sol kulaklara intratimpanik IGF-1 (Grup 1, n=4) veya deksametazon(Grup 2, n=3) verildi. Deneyi 7 sıçan tamamlayabildi.Bulgular: 90-80 dB 4/5 dalgalarda latans sürelerine kısalma gözlenmedi. 70-60 dB 4/5 dalgalarda latans sürelerinde kısalma gözlenmedi ancak ototoksisiteyi yavaşlatan ve durduran bir etki gözlendi. 50 dB 4/5 dalgalarda hem IGF-1 hemde deksametazon ototoksisiteyi iyileştiren etki gösterdi . Bu etki grup 2'de istatistiksel olarak anlamlı gözlenmedi ancak grup 1'de istatistiksel olarak anlamlı gözlendi.Sonuç: Sisplatin ototoksisitesinde intratimpanik IGF-1 ototoksisiteyi durduran ve işitme seviyesinde iyileşmeye yol açan bir ajan olduğu gözlenmiştir.
dc.description.abstractObjective: The aim of this study is to compare therapeutic effects of intratympanic dexamethasone and intratympanic IGF-1 treatments in cisplatin ototoxicity using electrophysiological evaluations.Materials and methods: Single dose of 16 mg/kg of cisplatin was administered intraperitoneally to the 12 rats. BAER tests were performed and ABR latencies were documented at basal condition, 72h post-cisplatin administration and after IT injection of dexamethasone or IGF-1. The right ears of the rats received only intratympanic saline injection and were considered as the control group for treatment. The left ears of the rats received either IGF-1 (Group 1, n=4) or dexamethasone (Group 2, n=3). 7 rats were able to complete the study.Results: At 90-80 dB or 70-60 dB hearing levels (HL) no improvement was observed in prolonged latency of 4/5 wave, although at 70-60 dB a beneficial effect was observed as the progression of ototoxicity was slowed down or stopped. At 50 dB HL prolonged latency of 4/5 wave was improved in response to both dexamethasone and IGF-1 treatments, while the the effect was statistically significant only in the IGF-1 group.Conclusion: Intratympanic IGF-1 could be a good choice for treatment of cisplatin induced ototoxicity, as it stops progression of ototoxicity and provides improvement in hearing levels.en_US
dc.languageTurkish
dc.language.isotr
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAttribution 4.0 United Statestr_TR
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectKulak Burun ve Boğaztr_TR
dc.subjectOtorhinolaryngology (Ear-Nose-Throat)en_US
dc.titleSisplatin ototoksisitesinde intratimpanik kortikosteroid ve IGF-1 tedavi etkilerinin araştırılması
dc.title.alternativeEvaluation of therapeutical effects of intratympanic corticostreoid and IGF-1 treatments in cisplatin induced ototoxicity
dc.typedoctoralThesis
dc.date.updated2020-12-01
dc.contributor.departmentKulak Burun Boğaz Anabilim Dalı
dc.subject.ytmCisplatin
dc.subject.ytmToxicity
dc.subject.ytmAdrenal cortex hormones
dc.subject.ytmInsulin like growth factor I
dc.subject.ytmDexamethasone
dc.subject.ytmRats
dc.identifier.yokid10102410
dc.publisher.instituteTıp Fakültesi
dc.publisher.universityANKARA ÜNİVERSİTESİ
dc.type.submedicineThesis
dc.identifier.thesisid419869
dc.description.pages69
dc.publisher.disciplineDiğer


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess